Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a study of repeated IT administrations of BO-112 in combination with ablative radiotherapy (SABR) and concurrent nivolumab in patients with metastatic PD-1/PD-L1-refractory NSCLC.
Epistemonikos ID: addc38c0432d0b05089cf0abba7f48bcd6353220
First added on: May 10, 2024